Endocrine 3 (Type 2 Diabetes | Non Cardio Risk )

Question 1

Canagliflozin

Answer 1

SGLT2 Inhibitor
- Inhibits SGLT2 to lower reabsorption of glucose
- Lowers Blood Sugar

• SGLT 1 Inhibition as well
• Increased Risk of Amputation

Question 2

Dapagliflozin

Answer 2

SGLT2 Inhibitor
- Inhibits SGLT2 to lower reabsorption of glucose
- Lowers Blood Sugar

Question 3

Empagliflozin

Answer 3

SGLT2 Inhibitor
- Inhibits SGLT2 to lower reabsorption of glucose
- Lowers Blood Sugar

Question 4

Ertugliflozin

Answer 4

SGLT2 Inhibitor
- Inhibits SGLT2 to lower reabsorption of glucose
- Lowers Blood Sugar

Question 5

Bexagliflozin

Answer 5

SGLT2 Inhibitor
- Inhibits SGLT2 to lower reabsorption of glucose
- Lowers Blood Sugar

No strong reduction in cardiovascular events

Question 6

Exenatide

Answer 6

DPP-4 Resistant GLP-1 Agonists that improves Glycemia by:
- Promotes Glucose Stimulated Insulin Secretion
- Inhibits Glucagon Secretion, thus, reduces Hepatic Glucose Production
- Inhibits Gastric Emptying, thus, less glucose in circulation
- Inhibits Appetite, thus, less body weight and less adiposity

Is a protein so it has to be injected
- Can form neutralizing antibodies
- No cardiovascular risk reduction

Question 7

Liraglutide

Answer 7

DPP-4 Resistant GLP-1 Agonists that improves Glycemia by:
- Promotes Glucose Stimulated Insulin Secretion
- Inhibits Glucagon Secretion, thus, reduces Hepatic Glucose Production
- Inhibits Gastric Emptying, thus, less glucose in circulation
- Inhibits Appetite, thus, less body weight and less adiposity

Is a protein so it has to be injected

Question 8

Albiglutide

Answer 8

DPP-4 Resistant GLP-1 Agonists that improves Glycemia by:
- Promotes Glucose Stimulated Insulin Secretion
- Inhibits Glucagon Secretion, thus, reduces Hepatic Glucose Production
- Inhibits Gastric Emptying, thus, less glucose in circulation
- Inhibits Appetite, thus, less body weight and less adiposity

Is a protein so it has to be injected

Question 9

Lixisenatide

Answer 9

DPP-4 Resistant GLP-1 Agonists that improves Glycemia by:
- Promotes Glucose Stimulated Insulin Secretion
- Inhibits Glucagon Secretion, thus, reduces Hepatic Glucose Production
- Inhibits Gastric Emptying, thus, less glucose in circulation
- Inhibits Appetite, thus, less body weight and less adiposity

Is a protein so it has to be injected

• No cardiovascular risk reduction

Question 10

Dulaglutide

Answer 10

DPP-4 Resistant GLP-1 Agonists that improves Glycemia by:
- Promotes Glucose Stimulated Insulin Secretion
- Inhibits Glucagon Secretion, thus, reduces Hepatic Glucose Production
- Inhibits Gastric Emptying, thus, less glucose in circulation
- Inhibits Appetite, thus, less body weight and less adiposity

Is a protein so it has to be injected

Question 11

Semaglutide

Answer 11

DPP-4 Resistant GLP-1 Agonists that improves Glycemia by:
- Promotes Glucose Stimulated Insulin Secretion
- Inhibits Glucagon Secretion, thus, reduces Hepatic Glucose Production
- Inhibits Gastric Emptying, thus, less glucose in circulation
- Inhibits Appetite, thus, less body weight and less adiposity

Is a protein so it has to be injected

Question 12

Sitagliptin

Answer 12

DPP-4 Inhibitor
- Prevents the breakdown of endogenous GLP-1

Taken Orally

Question 13

Vildagliptin

Answer 13

DPP-4 Inhibitor
- Prevents the breakdown of endogenous GLP-1

Taken Orally

Question 14

Saxagliptin

Answer 14

DPP-4 Inhibitor
- Prevents the breakdown of endogenous GLP-1

Taken Orally

• Increased risk of heart failure

Question 15

Alogliptin

Answer 15

DPP-4 Inhibitor
- Prevents the breakdown of endogenous GLP-1

Taken Orally

Question 16

Linagliptin

Answer 16

DPP-4 Inhibitor
- Prevents the breakdown of endogenous GLP-1

Taken Orally